BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25790771)

  • 1. Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis.
    He X; Chen P; Yang K; Liu B; Zhang Y; Wang F; Guo Z; Liu X; Lou J; Chen H
    Acta Haematol; 2015; 133(4):365-371. PubMed ID: 25790771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
    Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
    Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.
    Zhuo W; Zhang L; Ling J; Zhu B; Chen Z
    Leuk Lymphoma; 2012 Nov; 53(11):2245-52. PubMed ID: 22563815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.
    Ou WB
    Med Sci Monit; 2015 Jan; 21():213-8. PubMed ID: 25600314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis.
    Yan YL; Han F; Tan WM; Wu CP; Qin X
    Asian Pac J Cancer Prev; 2014; 15(16):6767-72. PubMed ID: 25169523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of MDM2 T309G polymorphism in susceptibility and prognosis of nonsmall cell lung cancer: a meta-analysis.
    Kong Q; Li P; Tian Q; Ha MW
    Genet Test Mol Biomarkers; 2014 May; 18(5):357-65. PubMed ID: 24673452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.
    Yin L; Shen G; Zhu B
    Thorac Cancer; 2020 Mar; 11(3):672-678. PubMed ID: 31970867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.
    Xue Z; Zhu X; Teng Y
    Med Sci Monit; 2016 Sep; 22():3186-90. PubMed ID: 27604213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.
    Economopoulos KP; Sergentanis TN
    Breast Cancer Res Treat; 2010 Feb; 120(1):211-6. PubMed ID: 19590949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between murine double minute 2 T309G polymorphism and risk of liver cancer.
    Tang T; Song X; Yang Z; Huang L; Wang W; Tan H
    Tumour Biol; 2014 Nov; 35(11):11353-7. PubMed ID: 25119589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.
    Zhuo W; Zhang L; Zhu B; Ling J; Chen Z
    PLoS One; 2012; 7(7):e41546. PubMed ID: 22844496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis.
    Ma HB; Huang T; Han F; Chen WY
    Asian Pac J Cancer Prev; 2012; 13(6):2841-6. PubMed ID: 22938470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of Murine Double Minute 2 Genotypes to Colorectal Cancer Risk in Taiwan.
    Yueh TC; Hung YW; Shih TC; Wu CN; Wang SC; Lai YL; Hsu SW; Wu MH; Fu CK; Wang YC; Ke TW; Chang WS; Tsai CW; Bau DT
    Cancer Genomics Proteomics; 2018; 15(5):405-411. PubMed ID: 30194081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relationship Between MDM2 T309G Polymorphism and Leukemia in the Chinese Population: Evidence from a Meta-Analysis.
    Zhao D; Liu T
    Clin Lab; 2017 Oct; 63(10):1639-1645. PubMed ID: 29035454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.
    Tang J; Shen L; Song S; An Z; Zhang C
    Tumour Biol; 2014 Jan; 35(1):779-84. PubMed ID: 23979978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is MDM2 SNP309 Variation a Risk Factor for Head and Neck Carcinoma?: An Updated Meta-Analysis Based on 11,552 Individuals.
    Zhuo X; Ye H; Li Q; Xiang Z; Zhang X
    Medicine (Baltimore); 2016 Mar; 95(9):e2948. PubMed ID: 26945408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.